騰訊暫守320港元 兩手準備騰訊購23552、沽23438
週四恆指先跌後反彈，全日波幅約350點，當日焦點有公布完業績先跌後急升的中國生物製藥(1177)，最高見11.78港元，上升一成，帶動藥股追好，石藥(1093)股價最高見16.24港元，上升4.7%。內地的醫藥帶量採購政策力度溫和，令醫藥股近星期造好，不過由於中藥已出現大幅反彈，投資者如憧憬石藥追落後，可留意石藥集團認購27355，行使價16.38港元，19年12月到期，有效槓桿約5.3倍。
另外騰訊(0700) 週四曾下試310港元水平，之後跌幅收窄，重上320港元收市。週三有外電指騰訊音樂正接受中國反壟斷調查，如壟斷屬實騰訊會被終止與全球多家主流音樂公司包括索尼、華納以及環球等的獨家許可協議。雖然股價週四重新靠穩，不過南非大股東Naspers即將分拆持有騰訊31%股權的公司上市，市場一直擔心此舉會為騰訊帶來沽售壓力，如投資者看淡騰訊，可留意騰訊控股認沽23438，行使價314.8港元，19年11月到期，有效槓桿約8.7倍。
不過資金多日來主力流入騰訊認購證，由8月26日至8月28日的3個交易日內，騰訊認購證累計約有6762萬港元資金淨流入。不過由於近日騰訊控股跌勢非常急，之前較熱門的認購證或已變得非常價外，如投資者看好騰訊，可留意騰訊控股認購23552，行使價340.2港元，19年12月到期，有效槓桿約7.9倍。
更多窩輪牛熊資訊：瑞銀證網站: www.ubs.com/hkwarrants卓素華董事
瑞銀亞洲股票衍生產品銷售部
本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人)，並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發，其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌，投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止，屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險，並諮詢專業顧問及查閱有關上市文件。UBS Securities Hong Kong Limited為結構性產品之流通量提供者，亦可能是唯一報價者或巿場參與者。c UBS 2019。版權所有。~重要聲明:
以上資訊由第三方提供，AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告，不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料，本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
